For advanced GC with SRC, CD3+ T cells were more infiltrated in PD-L1-positive tumors and further investigation of the cancer immunotherapy markers of SRC in GC may highlight targets for immunotherapy [26]. This evidence concerns the gene CD274 and cancer.